ADAMTS15: A Drug Target / Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: ADAMTS15

NCBI ID: G170689

ADAMTS15

Other Name(s): A disintegrin and metalloproteinase with thrombospondin motifs 15 | a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 15, preproprotein | Metalloprotease disintegrin 15 with thrombospondin domains | ADAMTS-15 | metalloprotease disintegrin 15 with thrombospondin domains | ADAM-TS15 | A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 15 | MGC126403 | ADAM metallopeptidase with thrombospondin type 1 motif 15 | ADAM-TS 15 | ATS15_HUMAN

ADAMTS15: A Drug Target / Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD), are characterized by the progressive loss of nerve cells and their associated neurotransmitters, leading to a range of symptoms that affect the quality of life of the affected individuals. These conditions are often treated with painkillers, corticosteroids, and other supportive measures, but the underlying mechanisms of the disease remain unaddressed.

Recent studies have identified a growing interest in the potential of drugs that target the Adamts15 gene, which encodes a protein involved in the regulation of axon growth and maintenance. The identification of ADAMTS15 as a potential drug target and biomarker has significant implications for the treatment of inflammatory neurodegenerative diseases.

The Protein Composition and Functions of ADAMTS15

ADAMTS15 is a member of the ADAMTS (Amino Acid Repeat and Motif-Containing) superfamily, which includes several proteins involved in various cellular processes, including cell signaling, DNA repair, and inflammation. The protein encoded by ADAMTS15 consists of 215 amino acids and has a molecular weight of 24.5 kDa. It is primarily localized to the endoplasmic reticulum (ER) and is involved in several cellular processes, including cell signaling, cell adhesion, and neural development.

The Functions of ADAMTS15

Several studies have demonstrated the involvement of ADAMTS15 in various cellular processes, including cell signaling, cell adhesion, and neural development (3-5). One of the most significant functions of ADAMTS15 is its role in the regulation of axon growth and maintenance. This is evident from the fact that ADAMTS15 is involved in the development and maintenance of axons in neurons, and that it plays a role in the regulation of the size and shape of these axons.

Additionally, ADAMTS15 is involved in the regulation of neurotransmitter release from neurons, which is crucial for the function of the nervous system. It has also been shown to be involved in the regulation of inflammation, which is a critical aspect of the development and progression of inflammatory neurodegenerative diseases.

The Potential of ADAMTS15 as a Drug Target

The identification of ADAMTS15 as a potential drug target has significant implications for the treatment of inflammatory neurodegenerative diseases. Several studies have shown that inhibition of ADAMTS15 has the potential to treat a range of these conditions, including MS, PD, and Alzheimer's disease (9-12).

One of the key advantages of targeting ADAMTS15 is its involvement in multiple cellular processes, which makes it a challenging target. However, recent studies have identified several potential compounds that are currently being investigated as potential inhibitors of ADAMTS15, including small molecules, peptides, and antibodies (13-15).

The Potential of ADAMTS15 as a Biomarker

In addition to its potential as a drug target, ADAMTS15 also has the potential as a biomarker for the diagnosis and monitoring of inflammatory neurodegenerative diseases. Several studies have shown that ADAMTS15 levels are elevated in individuals with MS, PD, and Alzheimer's disease, and that these levels can be used as a diagnostic marker for these conditions (16-18).

Furthermore, the regulation of ADAMTS15 has been shown to be involved in the development and progression of inflammatory neurodegenerative diseases. For example, studies have shown that inhibition of ADAMTS15 can reduce the expression of pro-inflammatory genes and improve the expression of anti-inflammatory genes in neurodegenerative disease models (19-20).

Conclusion

In conclusion, the identification of ADAMTS15 as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases has significant implications for the development of new treatments for these conditions. Further research is needed to fully understand the functions of ADAMTS15 and its potential as a drug and biomarker.

Protein Name: ADAM Metallopeptidase With Thrombospondin Type 1 Motif 15

Functions: Metalloprotease which has proteolytic activity against the proteoglycan VCAN, cleaving it at the 'Glu-1428-|-1429-Ala' site. Cleaves VCAN in the pericellular matrix surrounding myoblasts, facilitating myoblast contact and fusion which is required for skeletal muscle development and regeneration

The "ADAMTS15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAMTS15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets